Reaxys Integrates with LabNetwork to Offer Seamless Experience from Chemistry Research to Purchase

LabNetwork collaboration simplifies and accelerates purchasing decisions for chemical companies and researchers

Shanghai; Boston, MA, March 27, 2017

LabNetwork, WuXi AppTec’s global chemistry ecommerce platform company, today announced a new collaboration with Elsevier, a world-leading provider of scientific, technical and medical information products and services.

LabNetwork’s nearly four million commercially available discovery and research compounds will now be directly available to users of Reaxys, Elsevier’s premier chemistry database. The enhanced functionality means chemical companies and researchers, while using Reaxys, will also have access to both LabNetwork product availability and price information as a standard feature. The implementation deepens WuXi’s integration with chemists’ research and discovery workflows and expands exposure to WuXi ecommerce through LabNetwork.

Through the integration chemical companies and researchers can now enjoy product quality assurance that is guaranteed by WuXi, greater transparency over supply chains, and lower costs for a range of vital compounds on Reaxys. Researchers will also reap the advantages of a wider selection as LabNetwork sources compounds from more than 2,000 suppliers across the globe. Finally, the integration means that researchers will be able to easily compare the cost of buying a compound versus making it internally, allowing them to save time, accelerate research and better allocate budget resources.

“We are always looking for ways to support our customers to become more efficient and successful in their research,” commented Dr. Thibault GĂ©oui, Senior Director for Chemistry Solutions at Elsevier. “This integration with LabNetwork streamlines a process that thousands of researchers undertake many times a day. Speeding up these activities helps companies’ commercialize their own compounds faster, meaning that customers in rapidly developing markets, such as China, will benefit in particular. Not only because they will have peace of mind about the quality of the product they are investing in, but by boosting exports as well as improving in-country R&D.”

Dr. Xuanjia Peng, Head of LabNetwork, commented, “We’re excited to work with Elsevier, a world leading research tool in the chemistry and life science industries, to better serve the global research community with more cost effective research chemicals to lower research cost. LabNetwork is committed to provide researchers across the world with unprecedented access to LabNetwork’s commercially available compounds from a broad range of quality sources.”

---

About WuXi AppTec
WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities in small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics, WuXi platform is enabling more than 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi’s dream that “every drug can be made and every disease can be treated.” Please visit www.wuxiapptec.com

About LabNetwork
LabNetwork, a wholly owned subsidiary of the WuXi AppTec Group, is a global eCommerce platform with the vision of connecting suppliers and buyers of research products. Backed by WuXi AppTec’s expertise in R&D, sourcing, quality control, warehousing and logistics, LabNetwork brings trusted, novel, and high-quality compounds from WuXi's global network of qualified providers to the chemistry and research communities worldwide. Our mission is to enable scientists anywhere in the world to leverage the LabNetwork platform to conduct their research more efficiently and cost effectively. For more information, please visit www.LabNetwork.com

About Elsevier
Elsevier is a global information analytics company that helps institutions and professionals progress science, advance healthcare and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 35,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com

Media contact
Christopher Capot
Director, Corporate Relations, Elsevier
+1 917 704 5174
c.capot@elsevier.com